TempraMed Expands into Central America with Strategic Panama Partnership

TempraMed partners in Panama to address rising diabetes rates with its VIVI cooling solutions for secure insulin storage, aiming to reduce medication waste and costs.

TempraMed Technologies is making a significant move to broaden its footprint in Central America. The medical technology firm has announced a new partnership in Panama, aiming to introduce its specialized cooling solutions for pharmaceuticals to the region. This strategic expansion directly targets a rising clinical need for secure insulin storage, driven by increasing diabetes prevalence across Central America.

Addressing a Clear Clinical Demand

The expansion is underpinned by a pressing medical requirement. According to International Diabetes Federation estimates, over 312,000 adults in Panama are currently living with diabetes. The prevalence rate stands at approximately 11.1% and is projected to rise significantly by the year 2050.

TempraMed's technology is designed to maintain the efficacy of temperature-sensitive medications, even under fluctuating climatic conditions or during travel. Scientific publications support the role of such solutions in helping to reduce medication waste and lower overall healthcare costs.

Building a Distribution Network

To facilitate this market entry, the company has signed a non-binding letter of intent (LOI) with TEM Consulting International S.A. This partner operates a nationwide network in Panama, covering both public and private hospitals and clinics. The collaboration's objective is to make the VIVI product portfolio available through pharmacies, medical distributors, and retail stores.

A definitive distribution agreement is expected to be finalized within the next 90 days. This development follows the company's already established market presence in Israel, Turkey, and several European regions.

Strengthening Intellectual Property and Pipeline

Alongside its geographic growth, TempraMed is bolstering its global market position through intellectual property protection. In mid-March 2026, the Chinese patent office granted a patent for the so-called VIVI Box, a platform for storing multiple medications simultaneously.

Patent protection for this system is valid until October 2039. The VIVI Box is intended to complement the existing portfolio, which currently consists of four products, with a market launch anticipated by the end of 2026.

Market Reaction

Investors responded favorably to the expansion news. TempraMed shares advanced by 7.52% in today's trading, with the price currently quoted at €0.47. Market attention is now focused on the completion of the final trade agreement in Panama within the announced 90-day window.